Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
treosulfan + cytarabine + fludarabine
- Development stage
- Unknown
- Lead developer
- Ciceri Fabio
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
The FLAT regimen is a combination chemotherapy conditioning strategy consisting of treosulfan, cytarabine (Ara-C), and fludarabine. It is primarily investigated as a pre-transplant conditioning therapy for elderly patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing autologous stem cell transplantation (HSCT). Treosulfan acts as a bifunctional alkylating agent that induces DNA cross-linking, while fludarabine and cytarabine are antimetabolites that inhibit DNA synthesis. Fludarabine also serves as a biochemical modulator to enhance the cytotoxicity of other agents. This specific regimen, often referred to as FLAT-Auto in clinical trials led by Fabio Ciceri, aims to provide an effective yet tolerable consolidation strategy for older patients who may not be candidates for standard high-dose conditioning or allogeneic transplantation.
- Other names
- Treosulfan-cytarabine-fludarabine combinationFLAT regimen
02
Targets
DNA polymerase familyRNR (Ribonucleotide reductase)DNA
Beyond the preview
Go deeper on treosulfan + cytarabine + fludarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on treosulfan + cytarabine + fludarabine.